+44 7913 909111
info@titaniumprofessionals.com
guiding you onto the right path
The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patients.
Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020.Using the bacteria Lactiplantibacillus plantarum 299v as the microorganism, the team fermented pulses obtained from varying concentrations of black bean, black-eyed pea, green split pea, red lentil and pinto bean flours.
New data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.
The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.
Bayer announced that the investigational compound sevabertinib (BAY 2927088) has been granted Priority Review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2/ERBB2) mutations and who have received a prior systemic therapy.[1] Sevabertinib is an oral, small molecule, tyrosine kinase inhibitor (TKI).While there is no treatment to control or manage these neurodegenerative conditions, investigators at Case Western Reserve University, University Hospitals and the Louis Stokes Cleveland VA Medical Center have identified a new and promising drug to treat AD.
Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the ability of T cells to fight cancer and suppressed tumor growth across a range of cancer types in both mouse and human tumor models, the study, published in Cell, found.
Pfizer Inc. (NYSE: PFE) announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.In a study published in the Nature journal npj Drug Discovery, UCLA Health researchers targeted the protein clusterin (CLU), which is crucial in preventing the build-up of amyloid-beta plaques and
The center, or CRIB, is a collaborative effort between Purdue and Stony Brook universities.
In a new paper, Xia Ning, lead author of the study and a professor of biomedical informatics and computer science and engineering at The Ohio State University, introduces DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules that can serve as promising drug candidates.
Need help finding that new job? Leave your details with us and request a call back from one of our consultants.
Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you